Charles River Laboratories International, Inc. (CRL) EV/Assets Ratio: 1.56x
Is Charles River Laboratories International, Inc.’s EV/Assets ratio high or low?
Charles River Laboratories International, Inc.'s EV/Assets ratio of 1.56x is 20% below its 5-year average of 1.95x, near the low end of its 5-year range (1.01x–3.95x).
The EV/Assets ratio for Charles River Laboratories International, Inc. (CRL) is 1.56x as of Wednesday, June 10, 2026. It is above its 12-month average by 3.72% (1.50x).
CRL EV/Assets Ratio Chart
CRL Average EV/Assets Ratio Chart
CRL Current vs Average EV/Assets Ratio Chart
CRL EV/Assets Ratio Metrics
EV/ASSETS RATIO
1.56x
EV/ASSETS RATIO AVG TTM
1.50x
EV/ASSETS RATIO AVG 3Y
1.60x
EV/ASSETS RATIO AVG 5Y
1.95x
EV/ASSETS RATIO AVG 10Y
2.07x
EV/ASSETS RATIO AVG 15Y
1.98x
EV/ASSETS RATIO AVG 20Y
1.82x
CURRENT VS TTM AVG
+3.72%
CURRENT VS 3Y AVG
-2.26%
CURRENT VS 5Y AVG
-20.07%
CURRENT VS 10Y AVG
-24.57%
CURRENT VS 15Y AVG
-21.33%
CURRENT VS 20Y AVG
-14.25%
CRL Competitors' EV/Assets Ratio
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Charles River Laboratories International, Inc. (CRL) | — | 1.56x | 1.50x | 1.60x | 1.95x |
| Bio-Rad Laboratories, Inc. (BIO) | $7.89B | 0.89x | 0.88x | 0.89x | 0.99x |
| Hims & Hers Health, Inc. (HIMS) | $6.42B | 3.30x | 5.99x | 7.32x | 5.78x |
| Align Technology, Inc. (ALGN) | $12.56B | 1.84x | 1.76x | 2.56x | 3.77x |
| Hologic, Inc. (HOLX) | $16.97B | 1.91x | 1.84x | 1.98x | 2.08x |
| Moderna, Inc. (MRNA) | $18.40B | 1.55x | 1.14x | 1.48x | 2.53x |
| BioNTech SE (BNTX) | $21.81B | 0.44x | 0.55x | 0.54x | 1.39x |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 6.85x | 8.27x | 8.63x | 9.33x |
| Waters Corporation (WAT) | $23.83B | 1.43x | 4.12x | 4.55x | 5.47x |
| Veeva Systems Inc. (VEEV) | $27.37B | 2.85x | 4.64x | 5.33x | 7.00x |
Charles River Laboratories International, Inc. EV/Assets Ratio Formula & Definition
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Charles River Laboratories International, Inc. EV/Assets Ratio FAQ
- What is the EV/Assets ratio for Charles River Laboratories International, Inc. (CRL)?
- The EV/Assets ratio for CRL stock is 1.56x.
- Is Charles River Laboratories International, Inc.'s EV/Assets ratio high or low?
- Charles River Laboratories International, Inc.'s EV/Assets ratio of 1.56x is 20% below its 5-year average of 1.95x, near the low end of its 5-year range (1.01x–3.95x).
- What is the TTM average EV/Assets ratio for Charles River Laboratories International, Inc. (CRL)?
- The TTM average EV/Assets ratio for CRL stock is 1.50x.
- What is the 3Y average EV/Assets ratio for Charles River Laboratories International, Inc. (CRL)?
- The 3Y average EV/Assets ratio for CRL stock is 1.60x.
- What is the 5Y average EV/Assets ratio for Charles River Laboratories International, Inc. (CRL)?
- The 5Y average EV/Assets ratio for CRL stock is 1.95x.
- What is the 10Y average EV/Assets ratio for Charles River Laboratories International, Inc. (CRL)?
- The 10Y average EV/Assets ratio for CRL stock is 2.07x.
- What is the 15Y average EV/Assets ratio for Charles River Laboratories International, Inc. (CRL)?
- The 15Y average EV/Assets ratio for CRL stock is 1.98x.
- What is the 20Y average EV/Assets ratio for Charles River Laboratories International, Inc. (CRL)?
- The 20Y average EV/Assets ratio for CRL stock is 1.82x.
Charles River Laboratories International, Inc. EV/Assets Ratio History
| DATE | EV/ASSETS RATIO |
|---|---|
| 2026-06-10 | 1.56x |
| 2026-06-09 | 1.57x |
| 2026-06-08 | 1.55x |
| 2026-06-05 | 1.52x |
| 2026-06-04 | 1.55x |
| 2026-06-03 | 1.51x |
| 2026-06-02 | 1.48x |
| 2026-06-01 | 1.52x |
| 2026-05-29 | 1.51x |
| 2026-05-28 | 1.52x |
| 2026-05-27 | 1.41x |
| 2026-05-26 | 1.36x |
| 2026-05-22 | 1.39x |
| 2026-05-21 | 1.38x |
| 2026-05-20 | 1.36x |
| 2026-05-19 | 1.34x |
| 2026-05-18 | 1.32x |
| 2026-05-15 | 1.33x |
| 2026-05-14 | 1.38x |
| 2026-05-13 | 1.40x |
| 2026-05-12 | 1.44x |
| 2026-05-11 | 1.44x |
| 2026-05-08 | 1.50x |
| 2026-05-07 | 1.52x |
| 2026-05-06 | 1.65x |
| 2026-05-05 | 1.68x |
| 2026-05-04 | 1.59x |
| 2026-05-01 | 1.54x |
| 2026-04-30 | 1.55x |
| 2026-04-29 | 1.53x |
| 2026-04-28 | 1.55x |
| 2026-04-27 | 1.58x |
| 2026-04-24 | 1.57x |
| 2026-04-23 | 1.56x |
| 2026-04-22 | 1.67x |
| 2026-04-21 | 1.66x |
| 2026-04-20 | 1.68x |
| 2026-04-17 | 1.67x |
| 2026-04-16 | 1.62x |
| 2026-04-15 | 1.65x |
| 2026-04-14 | 1.64x |
| 2026-04-13 | 1.63x |
| 2026-04-10 | 1.61x |
| 2026-04-09 | 1.61x |
| 2026-04-08 | 1.61x |
| 2026-04-07 | 1.57x |
| 2026-04-06 | 1.56x |
| 2026-04-02 | 1.60x |
| 2026-04-01 | 1.61x |
| 2026-03-31 | 1.59x |
| 2026-03-30 | 1.50x |
| 2026-03-27 | 1.50x |
| 2026-03-26 | 1.54x |
| 2026-03-25 | 1.54x |
| 2026-03-24 | 1.50x |
| 2026-03-23 | 1.49x |
| 2026-03-20 | 1.46x |
| 2026-03-19 | 1.46x |
| 2026-03-18 | 1.48x |
| 2026-03-17 | 1.46x |
| 2026-03-16 | 1.45x |
| 2026-03-13 | 1.47x |
| 2026-03-12 | 1.45x |
| 2026-03-11 | 1.56x |
| 2026-03-10 | 1.55x |
| 2026-03-09 | 1.62x |
| 2026-03-06 | 1.60x |
| 2026-03-05 | 1.65x |
| 2026-03-04 | 1.64x |
| 2026-03-03 | 1.61x |
| 2026-03-02 | 1.63x |
| 2026-02-27 | 1.63x |
| 2026-02-26 | 1.61x |
| 2026-02-25 | 1.56x |
| 2026-02-24 | 1.55x |
| 2026-02-23 | 1.53x |
| 2026-02-20 | 1.56x |
| 2026-02-19 | 1.53x |
| 2026-02-18 | 1.49x |
| 2026-02-17 | 1.37x |
| 2026-02-13 | 1.38x |
| 2026-02-12 | 1.37x |
| 2026-02-11 | 1.41x |
| 2026-02-10 | 1.51x |
| 2026-02-09 | 1.54x |
| 2026-02-06 | 1.57x |
| 2026-02-05 | 1.53x |
| 2026-02-04 | 1.65x |
| 2026-02-03 | 1.65x |
| 2026-02-02 | 1.73x |
| 2026-01-30 | 1.71x |
| 2026-01-29 | 1.71x |
| 2026-01-28 | 1.75x |
| 2026-01-27 | 1.77x |
| 2026-01-26 | 1.79x |
| 2026-01-23 | 1.77x |
| 2026-01-22 | 1.80x |
| 2026-01-21 | 1.81x |
| 2026-01-20 | 1.76x |
| 2026-01-16 | 1.77x |
| 2026-01-15 | 1.79x |
| 2026-01-14 | 1.75x |
| 2026-01-13 | 1.76x |
| 2026-01-12 | 1.76x |
| 2026-01-09 | 1.78x |
| 2026-01-08 | 1.74x |
| 2026-01-07 | 1.75x |
| 2026-01-06 | 1.74x |
| 2026-01-05 | 1.69x |
| 2026-01-02 | 1.65x |
| 2025-12-31 | 1.63x |
| 2025-12-30 | 1.65x |
| 2025-12-29 | 1.66x |
| 2025-12-26 | 1.66x |
| 2025-12-24 | 1.66x |
| 2025-12-23 | 1.66x |
| 2025-12-22 | 1.66x |
| 2025-12-19 | 1.62x |
| 2025-12-18 | 1.60x |
| 2025-12-17 | 1.61x |
| 2025-12-16 | 1.61x |
| 2025-12-15 | 1.63x |
| 2025-12-12 | 1.59x |
| 2025-12-11 | 1.60x |
| 2025-12-10 | 1.60x |
| 2025-12-09 | 1.55x |
| 2025-12-08 | 1.55x |
| 2025-12-05 | 1.53x |
| 2025-12-04 | 1.53x |
| 2025-12-03 | 1.54x |
| 2025-12-02 | 1.47x |
| 2025-12-01 | 1.48x |
| 2025-11-28 | 1.49x |
| 2025-11-26 | 1.50x |
| 2025-11-25 | 1.49x |
| 2025-11-24 | 1.44x |
| 2025-11-21 | 1.43x |
| 2025-11-20 | 1.39x |
| 2025-11-19 | 1.39x |
| 2025-11-18 | 1.39x |
| 2025-11-17 | 1.39x |
| 2025-11-14 | 1.43x |
| 2025-11-13 | 1.44x |
| 2025-11-12 | 1.45x |
| 2025-11-11 | 1.46x |
| 2025-11-10 | 1.43x |
| 2025-11-07 | 1.43x |
| 2025-11-06 | 1.45x |
| 2025-11-05 | 1.43x |
| 2025-11-04 | 1.50x |
| 2025-11-03 | 1.51x |
| 2025-10-31 | 1.52x |
| 2025-10-30 | 1.51x |
| 2025-10-29 | 1.52x |
| 2025-10-28 | 1.57x |
| 2025-10-27 | 1.62x |
| 2025-10-24 | 1.63x |
| 2025-10-23 | 1.59x |
| 2025-10-22 | 1.56x |
| 2025-10-21 | 1.57x |
| 2025-10-20 | 1.55x |
| 2025-10-17 | 1.51x |
| 2025-10-16 | 1.49x |
| 2025-10-15 | 1.46x |
| 2025-10-14 | 1.45x |
| 2025-10-13 | 1.46x |
| 2025-10-10 | 1.43x |
| 2025-10-09 | 1.47x |
| 2025-10-08 | 1.48x |
| 2025-10-07 | 1.45x |
| 2025-10-06 | 1.49x |
| 2025-10-03 | 1.50x |
| 2025-10-02 | 1.49x |
| 2025-10-01 | 1.46x |
| 2025-09-30 | 1.36x |
| 2025-09-29 | 1.30x |
| 2025-09-26 | 1.31x |
| 2025-09-25 | 1.29x |
| 2025-09-24 | 1.32x |
| 2025-09-23 | 1.32x |
| 2025-09-22 | 1.35x |
| 2025-09-19 | 1.36x |
| 2025-09-18 | 1.37x |
| 2025-09-17 | 1.34x |
| 2025-09-16 | 1.33x |
| 2025-09-15 | 1.34x |
| 2025-09-12 | 1.34x |
| 2025-09-11 | 1.39x |
| 2025-09-10 | 1.34x |
| 2025-09-09 | 1.37x |
| 2025-09-08 | 1.40x |
| 2025-09-05 | 1.41x |
| 2025-09-04 | 1.40x |
| 2025-09-03 | 1.40x |
| 2025-09-02 | 1.40x |
| 2025-08-29 | 1.41x |
| 2025-08-28 | 1.41x |
| 2025-08-27 | 1.41x |
| 2025-08-26 | 1.41x |
| 2025-08-25 | 1.41x |
| 2025-08-22 | 1.40x |
| 2025-08-21 | 1.35x |
| 2025-08-20 | 1.39x |
| 2025-08-19 | 1.38x |
| 2025-08-18 | 1.37x |
| 2025-08-15 | 1.37x |
| 2025-08-14 | 1.36x |
| 2025-08-13 | 1.36x |
| 2025-08-12 | 1.34x |
| 2025-08-11 | 1.32x |
| 2025-08-08 | 1.31x |
| 2025-08-07 | 1.32x |
| 2025-08-06 | 1.32x |
| 2025-08-05 | 1.49x |
| 2025-08-04 | 1.49x |
| 2025-08-01 | 1.48x |
| 2025-07-31 | 1.50x |
| 2025-07-30 | 1.55x |
| 2025-07-29 | 1.56x |
| 2025-07-28 | 1.56x |
| 2025-07-25 | 1.55x |
| 2025-07-24 | 1.55x |
| 2025-07-23 | 1.49x |
| 2025-07-22 | 1.46x |
| 2025-07-21 | 1.37x |
| 2025-07-18 | 1.40x |
| 2025-07-17 | 1.41x |
| 2025-07-16 | 1.40x |
| 2025-07-15 | 1.40x |
| 2025-07-14 | 1.42x |
| 2025-07-11 | 1.43x |
| 2025-07-10 | 1.46x |
| 2025-07-09 | 1.43x |
| 2025-07-08 | 1.43x |
| 2025-07-07 | 1.40x |
| 2025-07-03 | 1.42x |
| 2025-07-02 | 1.42x |
| 2025-07-01 | 1.40x |
| 2025-06-30 | 1.38x |
| 2025-06-27 | 1.37x |
| 2025-06-26 | 1.38x |
| 2025-06-25 | 1.37x |
| 2025-06-24 | 1.36x |
| 2025-06-23 | 1.35x |
| 2025-06-20 | 1.35x |
| 2025-06-18 | 1.34x |
| 2025-06-17 | 1.34x |
| 2025-06-16 | 1.38x |
| 2025-06-13 | 1.37x |
| 2025-06-12 | 1.38x |
| 2025-06-11 | 1.38x |
| 2025-06-10 | 1.38x |
| 2025-06-09 | 1.35x |
| 2025-06-06 | 1.33x |
| 2025-06-05 | 1.31x |
| 2025-06-04 | 1.32x |
| 2025-06-03 | 1.29x |
| 2025-06-02 | 1.27x |
| 2025-05-30 | 1.27x |
| 2025-05-29 | 1.29x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James C. Foster